Citation Impact
Citing Papers
Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab
2012
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
2015
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
2012 Standout
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis
2011
The clinician’s guide to prevention and treatment of osteoporosis
2022
Clinician’s Guide to Prevention and Treatment of Osteoporosis
2014 Standout
UK clinical guideline for the prevention and treatment of osteoporosis
2017
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016--Executive Summary
2016
Osteoporosis
2019 Standout
Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday
2012
Clinical utility of denosumab for treatment of bone loss in men and women
2011
Benefits and Risks of Bisphosphonate Therapy for Osteoporosis
2012
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
2017
Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?
2014
Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long?
2012
Current options for the management of postmenopausal osteoporosis
2011
Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab
2013
Epidemiology and pathogenesis of osteonecrosis of the jaw
2011
Using Osteoporosis Therapies in Combination
2017
Management of severe osteoporosis
2015
2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis
2012
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
2017
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
2012
Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway
2018
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016
2016
Capturing Magnesium Ions via Microfluidic Hydrogel Microspheres for Promoting Cancellous Bone Regeneration
2021 Standout
Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy
2014
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX
2012
Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis
2016
Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective
2012
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis
2016
Addressing unmeasured confounding in comparative observational research
2018 StandoutNobel
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
2014 Standout
Postmenopausal Osteoporosis
2016
Works of Z. Man being referenced
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results
2007
A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
2012
Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk
2011
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial
2009
FIVE-YEAR DENOSUMAB TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FIRST TWO YEARS OF THE FREEDOM TRIAL EXTENSION
2011
The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
2011
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
2011